All In Biotech

Drug Trial Radar · NCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Oct 30, 2026

Study completion Apr 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

Conditions

  • Methamphetamine-dependence
  • Methamphetamine Abuse

Interventions

  • extended-release naltrexone (XR-NTX)Drug

    Once per three weeks injections of extended-release naltrexone

  • extended release bupropion (BUP-XL) tablets (BUP-XL)Drug

    Daily oral extended release bupropion tablets

  • iPLBDrug

    Once per three weeks injections of placebo

  • oPLBDrug

    Daily oral placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with at least 75% methamphetamine-negative urine drug screen tests during the evaluation period (i. e., Weeks 11-12)Time frame: 2 weeks (i. e., Weeks 11-12)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • University of California Los Angeles

    Los Angeles, California

  • University of California at San Diego

    San Diego, California

  • Indiana University

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Minnesota

    Minneapolis, Minnesota

  • CODA

    Portland, Oregon

  • MUSC/BHS

    Pickens, South Carolina

  • University of Tennessee

    Memphis, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.